<HTML>
<HEAD>
<TITLE>sv8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt">As filed with the
Securities and Exchange Commission on May&nbsp;5, 2004 Registration No.&nbsp;333-_____



<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM S-8</B>


<P align="center" style="font-size: 10pt">REGISTRATION STATEMENT UNDER<BR>
THE SECURITIES ACT OF 1933, AS AMENDED


<P align="center" style="font-size: 24pt"><B>Genentech, Inc.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">94-2345624</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(State of Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification No.)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">1 DNA Way</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">South San Francisco, California
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">94080-4990</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>Genentech, Inc.<BR>
1999 Stock Plan, as amended and restated on 2/13/03<BR>
1991 Employee Stock Plan, as amended effective 4/23/03<BR>
2004 Equity Incentive Plan</B>



<P align="center" style="font-size: 10pt">(Full titles of the plans)



<P align="center" style="font-size: 10pt"><B>Stephen G. Juelsgaard, Esq.<BR>
Executive Vice President, General Counsel and Secretary<BR>
Genentech, Inc.<BR>
1 DNA Way<BR>
South San Francisco, California 94080-4990</B>



<P align="center" style="font-size: 10pt">(Name and address of agent for service)



<P align="center" style="font-size: 10pt">(650)&nbsp;225-1000



<P align="center" style="font-size: 10pt">(Telephone number, including area code, of agent for service)



<P align="center" style="font-size: 10pt"><B>CALCULATION OF REGISTRATION FEE</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Proposed Maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Proposed Maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Title of Securities</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Offering</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Aggregate</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Amount of</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>to be Registered</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Amount to be Registered</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Price per Share (2)</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Offering Price (2)</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Registration Fee</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Common stock, par value
$.02 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">25,000,000 shares(1)<BR>(1999
Stock Plan)</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">121.105</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,027,625,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">383,600.09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Common stock, par value
$.02 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">2,000,000 shares(1)<BR>(1991
Employee Stock Plan)</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">121.105</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">242,210,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">30,688.01</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Common stock, par value
$.02 per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">40,000,000 shares(1)<BR>(2004 Equity
Incentive Plan)</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">121.105</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,844,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">613,760.14</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt">(1)&nbsp;Genentech, Inc. announced a two-for-one stock split in the form of a
stock dividend on April&nbsp;16, 2004. In addition to the 67,000,000 shares
of common stock referenced above, this Registration Statement shall also
cover the 67,000,000 shares of common stock that will be additionally
reserved for grant under Genentech&#146;s stock plans listed above as a
result of the two-for-one stock split. The record date for the stock split was
April&nbsp;28, 2004 and the distribution date for the stock split is May&nbsp;12,
2004. This Registration Statement shall also cover any additional shares of the registrant&#146;s common stock that become issuable by reason
of any other stock dividend, stock split, recapitalization or other
similar transaction effected without the registrant&#146;s receipt of
consideration that results in an increase in the number of the
registrant&#146;s outstanding shares of common stock.


<P align="left" style="font-size: 10pt">(2)&nbsp;Estimated solely for the purpose of calculating the registration fee
pursuant to Rule&nbsp;457 under the Securities Act of 1933, as amended, on
the basis of $121.105 per share, the average of the high and low
prices per share of the common stock on May&nbsp;4, 2004, as reported on
the New York Stock Exchange.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PART II: INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;3: Incorporation of Documents by Reference</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#002">Item&nbsp;4: Description of Securities</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#003">Item&nbsp;5: Interests of Named Experts and Counsel</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">Item&nbsp;6: Indemnification of Directors and Officers</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#005">Item&nbsp;7: Exemption from Registration Claimed</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">Item&nbsp;8: Exhibits</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#007">Item&nbsp;9: Undertakings</A></TD></TR>
<TR><TD colspan="9"><A HREF="#008">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">POWER OF ATTORNEY</A></TD></TR>
<TR><TD colspan="9"><A HREF="#010">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="f98607exv5.txt">EXHIBIT 5</A></TD></TR>
<TR><TD colspan="9"><A HREF="f98607exv15w1.txt">EXHIBIT 15.1</A></TD></TR>
<TR><TD colspan="9"><A HREF="f98607exv23w1.txt">EXHIBIT 23.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "PART II: INFORMATION REQUIRED IN THE REGISTRATION STATEMENT" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>PART II: INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>

<!-- link2 "Item&nbsp;3: Incorporation of Documents by Reference" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;3: Incorporation of Documents by Reference</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this Registration Statement, &#147;Genentech,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
Genentech, Inc. The Securities and Exchange Commission, or SEC, allows us to
&#147;incorporate by reference&#148; the information we file with it, which means we can
disclose important information by referring to those documents. The
information included in the following documents is incorporated by reference
and is considered to be a part of this Registration Statement. The most recent
information that we file with the SEC automatically updates and supersedes more
dated information. We have previously filed the following documents with the
SEC and incorporate them by reference into this Registration Statement:


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Our annual report on Form 10-K for the year ended December&nbsp;31, 2003;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Our quarterly report on Form 10-Q for the quarter ended March&nbsp;31,
2004; and


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The description under the heading &#147;Description of Capital Stock&#148;
relating to our common stock in the prospectus included in our Amendment No.&nbsp;2
to the Registration Statement on Form S-3 (Registration No.&nbsp;333-88651) filed
with the SEC on October&nbsp;20, 1999, and the description under the heading
&#147;Description of Capital Stock&#148; relating to the common stock in the our final
prospectus filed with the SEC on October&nbsp;21, 1999 pursuant to Rule 424(b) under
the Securities Act of 1933, as amended, which is commonly known as the
Securities Act, including any amendment or report filed for the purpose of
updating that description.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also incorporate by reference all documents subsequently filed by us
pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934, as amended, which is commonly known as the Exchange Act, until all of the
shares registered under this Registration Statement are sold.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will provide without charge to each person to whom a prospectus is
delivered, including any beneficial owner, a copy of any or all of the
information that has been incorporated by reference in this Registration
Statement. If you would like to obtain this information from us, please direct
your request to the Investor Relations Department, either in writing or by
telephone, to Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, Attention Investor Relations (650)&nbsp;225-1260.

<!-- link2 "Item&nbsp;4: Description of Securities" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;4: Description of Securities</B>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;5: Interests of Named Experts and Counsel" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;5: Interests of Named Experts and Counsel</B>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stephen G. Juelsgaard, Executive Vice President, General Counsel and
Secretary of Genentech, is an executive officer of Genentech and has received
options to purchase common stock under our 1999 Stock Plan and our 1991
Employee Stock Plan.

<!-- link2 "Item&nbsp;6: Indemnification of Directors and Officers" -->
<DIV align="left"><A NAME="004"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;6: Indemnification of Directors and Officers</B>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation limits, to the fullest extent permitted
by Delaware corporate law, the personal liability of directors for monetary
damages for breach of their fiduciary duties.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 of the General Corporation Law of the State of Delaware (the
&#147;DGCL&#148;) provides, in summary, that directors and officers of Delaware
corporations are entitled, under certain circumstances, to be indemnified
against all expenses and liabilities (including attorneys&#146; fees) incurred by
them as a result of suits brought against them in their capacity as a director
or officer, if they acted in good faith and in a manner they reasonably
believed to be in or not opposed to the best interests of the corporation, and
with respect to any criminal action or proceeding, if they had no reasonable
cause to believe their conduct was unlawful; provided, that no indemnification
may be made against expenses in respect of any claim, issue or matter as to
which they shall have been adjudged to be liable to the


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">corporation, unless and only to the extent that the court in which such
action or suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case,
they are fairly and reasonably entitled to indemnity for such expenses which
the court shall deem proper. Any such indemnification may be made by the
corporation only as authorized in each specific case upon a determination by
the stockholders or disinterested directors that indemnification is proper
because the indemnitee has met the applicable standard of conduct.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may provide similar indemnification to our
officers, employees and agents as it deems appropriate and as authorized by
Delaware law. We may purchase insurance on behalf of any director, officer,
employee or agent against any expense incurred by such person in his or her
capacity.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation also provides that Roche Holdings, Inc.,
or Roche, and the officers
or directors of Roche, which is our majority
stockholder, will not be presumed liable to us or our stockholders for breach
of any fiduciary duty or duty of loyalty, failure to act in the best interests
of Genentech, or receipt of any improper personal benefit, simply because Roche
or any director or officer of Roche, in good faith, takes any action, exercises
any right or gives or withholds any consent with respect to any agreement or
contract between Roche and Genentech.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, Roche will not be liable to us or our stockholders for breach
of any fiduciary duty if Roche pursues or acquires a potential corporate
opportunity of ours or does not inform us of a potential corporate opportunity.
If a director, officer or employee of Genentech who is also a director, officer
or employee of Roche knows of a potential transaction or matter that may be a
corporate opportunity both for Genentech and Roche, the director, officer or
employee is entitled to offer the corporate opportunity to us or Roche as the
director, officer or employee deems appropriate under the circumstances in his
or her sole discretion, and no such director, officer or employee will be
liable to us or our stockholders for breach of any fiduciary duty or duty of
loyalty or failure to act in our best interests or the derivation of any
improper personal benefit by reason of the fact that such director, officer or
employee offered such corporate opportunity to Roche (rather than to us) or did
not communicate information regarding such corporate opportunity to us, or
Roche pursues or acquires such corporate opportunity for itself or directs such
corporate opportunity to another person or does not communicate the corporate
opportunity to us.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Roche nor any officer or director thereof shall be liable to us or
our stockholders for breach of any fiduciary duty or duty of loyalty or failure
to act in (or not opposed to) our best interests or the derivation of any
improper personal benefit by reason of the fact that Roche or an officer or
director thereof in good faith takes any action or exercises any rights or
gives or withholds any consent in connection with any agreement or contract
between Roche and Genentech. No vote cast or other action taken by any person
who is an officer, director or other representative of Roche, which vote is
cast or action is taken by such person in his capacity as a director of
Genentech, shall constitute an action of or the exercise of a right by or a
consent of Roche for the purpose of any such agreement or contract.

<!-- link2 "Item&nbsp;7: Exemption from Registration Claimed" -->
<DIV align="left"><A NAME="005"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7: Exemption from Registration Claimed</B>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;8: Exhibits" -->
<DIV align="left"><A NAME="006"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8: Exhibits</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Number</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Stephen G. Juelsgaard, Esq.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Genentech, Inc. 1999 Stock Plan, as amended and restated on 2/13/03(1)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Genentech, Inc. 1991 Employee Stock Plan, as amended on 4/23/03(2)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.18
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Genentech, Inc. 2004 Equity Incentive Plan(3)</TD>
</TR>

<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">15.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Letter re: Unaudited Financial
Information.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Ernst &#038; Young LLP, Independent Auditors</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Stephen G. Juelsgaard, Esq. is contained in Exhibit&nbsp;5 to this Registration Statement</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney is contained in the signature pages</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>




<P>

<HR size="1" width="18%" align="left" noshade>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="right">(1)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Previously filed as Exhibit&nbsp;10.9 to our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2003.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD width="1%" nowrap align="right">(2)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Previously filed as Exhibit&nbsp;10.10 to our Annual Report on Form 10-K for the year ended December&nbsp;31, 2003.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD width="1%" nowrap align="right">(3)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Previously filed as Exhibit&nbsp;10.18 to our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2004.</TD>
</TR>

</TABLE>


<!-- link2 "Item&nbsp;9: Undertakings" -->
<DIV align="left"><A NAME="007"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9: Undertakings</B>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The undersigned registrant hereby undertakes:</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(a)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(i)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To include any prospectus required by section
10(a)(3) of the Securities Act;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(ii)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental
change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form
of prospectus filed with the SEC pursuant to Rule 424(b) if,
in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price
set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(iii)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To include any material information with respect
to the plan of distribution not previously disclosed in the
registration statement or any material change to such
information in the registration statement;</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><I>&nbsp;</I></TD>
    <TD width="1%"><I>&nbsp;</I></TD>
    <TD><I>Provided, however, </I>that paragraphs (a)(i) and (a)(ii) do not apply
if the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports
filed by the issuer pursuant to section 13 or section 15(d) of the
Exchange Act that are incorporated by reference herein.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(b)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities
offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(c)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold
at the termination of the offering.</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant&#146;s annual report pursuant to Section 13(a) or Section 15(d) of
the Exchange Act (and, where applicable, each filing of an employee
benefit plan&#146;s annual report pursuant to section 15(d) of the Exchange
Act) that is incorporated by reference in the Registration Statement shall
be
</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>deemed to be a new registration statement relating to the securities
offered herein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by
the final adjudication of such issue.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>

<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="008"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended,
the undersigned registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8 and has duly
caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of South San Francisco,
State of California, on May&nbsp;5, 2004.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>GENENTECH, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">     /s/ STEPHEN G. JUELSGAARD
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD>Stephen G. Juelsgaard&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD>Executive Vice President, General Counsel and Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>
<!-- link1 "POWER OF ATTORNEY" -->
<DIV align="left"><A NAME="009"></A></DIV>

<P align="center" style="font-size: 10pt"><B>POWER OF ATTORNEY</B>




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>KNOW ALL PERSONS BY THESE PRESENTS</B>, that each person whose signature
appears below constitutes and appoints Stephen G. Juelsgaard and Roy C.
Hardiman, and each or any one of them, his true and lawful attorney-in-fact and
agent, with full power of substitution and resubstitution, for him and in his
name, place and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this Registration
Statement, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, or any of them, or their or his
substitutes or substitute, may lawfully do or cause to be done by virtue
hereof.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Signature</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Title</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Date</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" nowrap valign="top">/s/  ARTHUR D. LEVINSON<BR>
<HR size="1" noshade>
Arthur D. Levinson</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Principal Executive Officer<BR>
and Chairman
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  LOUIS J. LAVIGNE, JR.<BR>
<HR size="1" noshade>
Louis J. Lavigne, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Principal Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  JOHN M. WHITING<BR>
<HR size="1" noshade>
John M. Whiting</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Principal Accounting Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  HERBERT W. BOYER<BR>
<HR size="1" noshade>
Herbert W. Boyer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  WILLIAM M. BURNS<BR>
<HR size="1" noshade>
William M. Burns</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  ERICH HUNZIKER<BR>
<HR size="1" noshade>
Erich Hunziker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  JONATHAN K.C. KNOWLES<BR>
<HR size="1" noshade>
Jonathan K.C. Knowles</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  MARK RICHMOND<BR>
<HR size="1" noshade>
Mark Richmond</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/  CHARLES A. SANDERS<BR>
<HR size="1" noshade>
Charles A. Sanders</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">May&nbsp;5, 2004</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="010"></A></DIV>

<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Number</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Stephen G. Juelsgaard, Esq.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Genentech, Inc. 1999 Stock Plan, as amended and restated on 2/13/03(1)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Genentech, Inc. 1991 Employee Stock Plan, as amended on 4/23/03(2)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.18
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Genentech, Inc. 2004 Equity Incentive Plan(3)</TD>
</TR>

<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">15.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Letter re: Unaudited Interim
Financial Information</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Ernst &#038; Young LLP, Independent Auditors</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Stephen G. Juelsgaard, Esq. is contained in Exhibit&nbsp;5 to this Registration Statement</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney is contained in the signature pages</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>




<P>

<HR size="1" width="18%" align="left" noshade>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="right">(1)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Previously filed as Exhibit&nbsp;10.9 to our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2003.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD width="1%" nowrap align="right">(2)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Previously filed as Exhibit&nbsp;10.10 to our Annual Report on Form 10-K for the year ended December&nbsp;31, 2003.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD width="1%" nowrap align="right">(3)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Previously filed as Exhibit&nbsp;10.18 to our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2004.</TD>
</TR>

</TABLE>




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "f98607sv8.htm", "description": "FORM S-8", "secsgml_size_bytes": 44117}]
{"company-data": {"conformed-name": "GENENTECH INC", "cik": "0000318771", "assigned-sic": "2834", "irs-number": "942347624", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-115219", "film-number": "04784263"}, "business-address": {"street1": "1 DNA WAY", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "650-225-1000"}, "mail-address": {"street1": "1 DNA WAY", "street2": ".", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080"}}
sv8
Table of Contents
As filed with the
Securities and Exchange Commission on May 5, 2004 Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933, AS AMENDED
Genentech, Inc.
(Exact name of registrant as specified in its charter)
Delaware
94-2345624
(State of Incorporation)
(I.R.S. Employer Identification No.)
1 DNA Way
South San Francisco, California
94080-4990
(Address of principal executive offices)
(Zip Code)
Genentech, Inc.
1999 Stock Plan, as amended and restated on 2/13/03
1991 Employee Stock Plan, as amended effective 4/23/03
2004 Equity Incentive Plan
(Full titles of the plans)
Stephen G. Juelsgaard, Esq.
Executive Vice President, General Counsel and Secretary
Genentech, Inc.
1 DNA Way
South San Francisco, California 94080-4990
(Name and address of agent for service)
(650) 225-1000
(Telephone number, including area code, of agent for service)
CALCULATION OF REGISTRATION FEE
Proposed Maximum
Proposed Maximum
Title of Securities
Offering
Aggregate
Amount of
to be Registered
Amount to be Registered
Price per Share (2)
Offering Price (2)
Registration Fee
Common stock, par value
$.02 per share
25,000,000 shares(1)
(1999
Stock Plan)
$
121.105
$
3,027,625,000
$
383,600.09
Common stock, par value
$.02 per share
2,000,000 shares(1)
(1991
Employee Stock Plan)
$
121.105
$
242,210,000
$
30,688.01
Common stock, par value
$.02 per share
40,000,000 shares(1)
(2004 Equity
Incentive Plan)
$
121.105
$
4,844,200,000
$
613,760.14
(1) Genentech, Inc. announced a two-for-one stock split in the form of a
stock dividend on April 16, 2004. In addition to the 67,000,000 shares
of common stock referenced above, this Registration Statement shall also
cover the 67,000,000 shares of common stock that will be additionally
reserved for grant under Genentech's stock plans listed above as a
result of the two-for-one stock split. The record date for the stock split was
April 28, 2004 and the distribution date for the stock split is May 12,
2004. This Registration Statement shall also cover any additional shares of the registrant's common stock that become issuable by reason
of any other stock dividend, stock split, recapitalization or other
similar transaction effected without the registrant's receipt of
consideration that results in an increase in the number of the
registrant's outstanding shares of common stock.
(2) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457 under the Securities Act of 1933, as amended, on
the basis of $121.105 per share, the average of the high and low
prices per share of the common stock on May 4, 2004, as reported on
the New York Stock Exchange.
TABLE OF CONTENTS
PART II: INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3: Incorporation of Documents by Reference
Item 4: Description of Securities
Item 5: Interests of Named Experts and Counsel
Item 6: Indemnification of Directors and Officers
Item 7: Exemption from Registration Claimed
Item 8: Exhibits
Item 9: Undertakings
SIGNATURES
POWER OF ATTORNEY
EXHIBIT INDEX
EXHIBIT 5
EXHIBIT 15.1
EXHIBIT 23.1
Table of Contents
PART II: INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3: Incorporation of Documents by Reference
In this Registration Statement, "Genentech," "we," "us" and "our" refer to
Genentech, Inc. The Securities and Exchange Commission, or SEC, allows us to
"incorporate by reference" the information we file with it, which means we can
disclose important information by referring to those documents. The
information included in the following documents is incorporated by reference
and is considered to be a part of this Registration Statement. The most recent
information that we file with the SEC automatically updates and supersedes more
dated information. We have previously filed the following documents with the
SEC and incorporate them by reference into this Registration Statement:
(a) Our annual report on Form 10-K for the year ended December 31, 2003;
(b) Our quarterly report on Form 10-Q for the quarter ended March 31,
2004; and
(c) The description under the heading "Description of Capital Stock"
relating to our common stock in the prospectus included in our Amendment No. 2
to the Registration Statement on Form S-3 (Registration No. 333-88651) filed
with the SEC on October 20, 1999, and the description under the heading
"Description of Capital Stock" relating to the common stock in the our final
prospectus filed with the SEC on October 21, 1999 pursuant to Rule 424(b) under
the Securities Act of 1933, as amended, which is commonly known as the
Securities Act, including any amendment or report filed for the purpose of
updating that description.
We also incorporate by reference all documents subsequently filed by us
pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934, as amended, which is commonly known as the Exchange Act, until all of the
shares registered under this Registration Statement are sold.
We will provide without charge to each person to whom a prospectus is
delivered, including any beneficial owner, a copy of any or all of the
information that has been incorporated by reference in this Registration
Statement. If you would like to obtain this information from us, please direct
your request to the Investor Relations Department, either in writing or by
telephone, to Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, Attention Investor Relations (650) 225-1260.
Item 4: Description of Securities
Not applicable.
Item 5: Interests of Named Experts and Counsel
Stephen G. Juelsgaard, Executive Vice President, General Counsel and
Secretary of Genentech, is an executive officer of Genentech and has received
options to purchase common stock under our 1999 Stock Plan and our 1991
Employee Stock Plan.
Item 6: Indemnification of Directors and Officers
Our certificate of incorporation limits, to the fullest extent permitted
by Delaware corporate law, the personal liability of directors for monetary
damages for breach of their fiduciary duties.
Section 145 of the General Corporation Law of the State of Delaware (the
"DGCL") provides, in summary, that directors and officers of Delaware
corporations are entitled, under certain circumstances, to be indemnified
against all expenses and liabilities (including attorneys' fees) incurred by
them as a result of suits brought against them in their capacity as a director
or officer, if they acted in good faith and in a manner they reasonably
believed to be in or not opposed to the best interests of the corporation, and
with respect to any criminal action or proceeding, if they had no reasonable
cause to believe their conduct was unlawful; provided, that no indemnification
may be made against expenses in respect of any claim, issue or matter as to
which they shall have been adjudged to be liable to the
Table of Contents
corporation, unless and only to the extent that the court in which such
action or suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case,
they are fairly and reasonably entitled to indemnity for such expenses which
the court shall deem proper. Any such indemnification may be made by the
corporation only as authorized in each specific case upon a determination by
the stockholders or disinterested directors that indemnification is proper
because the indemnitee has met the applicable standard of conduct.
Our board of directors may provide similar indemnification to our
officers, employees and agents as it deems appropriate and as authorized by
Delaware law. We may purchase insurance on behalf of any director, officer,
employee or agent against any expense incurred by such person in his or her
capacity.
Our
certificate of incorporation also provides that Roche Holdings, Inc.,
or Roche, and the officers
or directors of Roche, which is our majority
stockholder, will not be presumed liable to us or our stockholders for breach
of any fiduciary duty or duty of loyalty, failure to act in the best interests
of Genentech, or receipt of any improper personal benefit, simply because Roche
or any director or officer of Roche, in good faith, takes any action, exercises
any right or gives or withholds any consent with respect to any agreement or
contract between Roche and Genentech.
In addition, Roche will not be liable to us or our stockholders for breach
of any fiduciary duty if Roche pursues or acquires a potential corporate
opportunity of ours or does not inform us of a potential corporate opportunity.
If a director, officer or employee of Genentech who is also a director, officer
or employee of Roche knows of a potential transaction or matter that may be a
corporate opportunity both for Genentech and Roche, the director, officer or
employee is entitled to offer the corporate opportunity to us or Roche as the
director, officer or employee deems appropriate under the circumstances in his
or her sole discretion, and no such director, officer or employee will be
liable to us or our stockholders for breach of any fiduciary duty or duty of
loyalty or failure to act in our best interests or the derivation of any
improper personal benefit by reason of the fact that such director, officer or
employee offered such corporate opportunity to Roche (rather than to us) or did
not communicate information regarding such corporate opportunity to us, or
Roche pursues or acquires such corporate opportunity for itself or directs such
corporate opportunity to another person or does not communicate the corporate
opportunity to us.
Neither Roche nor any officer or director thereof shall be liable to us or
our stockholders for breach of any fiduciary duty or duty of loyalty or failure
to act in (or not opposed to) our best interests or the derivation of any
improper personal benefit by reason of the fact that Roche or an officer or
director thereof in good faith takes any action or exercises any rights or
gives or withholds any consent in connection with any agreement or contract
between Roche and Genentech. No vote cast or other action taken by any person
who is an officer, director or other representative of Roche, which vote is
cast or action is taken by such person in his capacity as a director of
Genentech, shall constitute an action of or the exercise of a right by or a
consent of Roche for the purpose of any such agreement or contract.
Item 7: Exemption from Registration Claimed
Not applicable.
Item 8: Exhibits
Exhibit
Number
Description
5
Opinion of Stephen G. Juelsgaard, Esq.
10.9
Genentech, Inc. 1999 Stock Plan, as amended and restated on 2/13/03(1)
10.10
Genentech, Inc. 1991 Employee Stock Plan, as amended on 4/23/03(2)
Table of Contents
10.18
Genentech, Inc. 2004 Equity Incentive Plan(3)
15.1
Letter re: Unaudited Financial
Information.
23.1
Consent of Ernst & Young LLP, Independent Auditors
23.2
Consent of Stephen G. Juelsgaard, Esq. is contained in Exhibit 5 to this Registration Statement
24
Power of Attorney is contained in the signature pages
(1)
Previously filed as Exhibit 10.9 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2003.
(2)
Previously filed as Exhibit 10.10 to our Annual Report on Form 10-K for the year ended December 31, 2003.
(3)
Previously filed as Exhibit 10.18 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004.
Item 9: Undertakings
1.
The undersigned registrant hereby undertakes:
(a)
To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by section
10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental
change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form
of prospectus filed with the SEC pursuant to Rule 424(b) if,
in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price
set forth in the "Calculation of Registration Fee" table in
the effective registration statement.
(iii)
To include any material information with respect
to the plan of distribution not previously disclosed in the
registration statement or any material change to such
information in the registration statement;
Provided, however,
that paragraphs (a)(i) and (a)(ii) do not apply
if the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports
filed by the issuer pursuant to section 13 or section 15(d) of the
Exchange Act that are incorporated by reference herein.
(b)
That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities
offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(c)
To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold
at the termination of the offering.
2.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of
the Exchange Act (and, where applicable, each filing of an employee
benefit plan's annual report pursuant to section 15(d) of the Exchange
Act) that is incorporated by reference in the Registration Statement shall
be
Table of Contents
deemed to be a new registration statement relating to the securities
offered herein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
3.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by
the final adjudication of such issue.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the undersigned registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8 and has duly
caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of South San Francisco,
State of California, on May 5, 2004.
GENENTECH, INC.
By:
/s/ STEPHEN G. JUELSGAARD
Name:
Stephen G. Juelsgaard
Title:
Executive Vice President, General Counsel and Secretary
Table of Contents
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS
, that each person whose signature
appears below constitutes and appoints Stephen G. Juelsgaard and Roy C.
Hardiman, and each or any one of them, his true and lawful attorney-in-fact and
agent, with full power of substitution and resubstitution, for him and in his
name, place and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this Registration
Statement, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, or any of them, or their or his
substitutes or substitute, may lawfully do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature
Title
Date
/s/  ARTHUR D. LEVINSON
Arthur D. Levinson
Principal Executive Officer
and Chairman
May 5, 2004
/s/  LOUIS J. LAVIGNE, JR.
Louis J. Lavigne, Jr.
Principal Financial Officer
May 5, 2004
/s/  JOHN M. WHITING
John M. Whiting
Principal Accounting Officer
May 5, 2004
/s/  HERBERT W. BOYER
Herbert W. Boyer
Director
May 5, 2004
/s/  WILLIAM M. BURNS
William M. Burns
Director
May 5, 2004
/s/  ERICH HUNZIKER
Erich Hunziker
Director
May 5, 2004
/s/  JONATHAN K.C. KNOWLES
Jonathan K.C. Knowles
Director
May 5, 2004
/s/  MARK RICHMOND
Mark Richmond
Director
May 5, 2004
/s/  CHARLES A. SANDERS
Charles A. Sanders
Director
May 5, 2004
Table of Contents
EXHIBIT INDEX
Exhibit
Number
Description
5
Opinion of Stephen G. Juelsgaard, Esq.
10.9
Genentech, Inc. 1999 Stock Plan, as amended and restated on 2/13/03(1)
10.10
Genentech, Inc. 1991 Employee Stock Plan, as amended on 4/23/03(2)
10.18
Genentech, Inc. 2004 Equity Incentive Plan(3)
15.1
Letter re: Unaudited Interim
Financial Information
23.1
Consent of Ernst & Young LLP, Independent Auditors
23.2
Consent of Stephen G. Juelsgaard, Esq. is contained in Exhibit 5 to this Registration Statement
24
Power of Attorney is contained in the signature pages
(1)
Previously filed as Exhibit 10.9 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2003.
(2)
Previously filed as Exhibit 10.10 to our Annual Report on Form 10-K for the year ended December 31, 2003.
(3)
Previously filed as Exhibit 10.18 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004.